Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Mar 16, 2017Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savingsToday, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...
- Mar 16, 2017Si ritiene che la durata prolungata della batteria dei dispositivi di Boston Scientific contribuisca alla riduzione degli interventi di sostituzione e delle complicanze e che possa potenzialmente determinare risparmi economici significativi
Oggi, il National Institute for Health and Care Excellence (NICE) ha emanato delle indicazioni mediche e tecnologiche nelle quali si consiglia l’uso dei defibrillatori per la terapia di...
- Mar 16, 2017Die verlängerte Funktionsdauer der Geräte trägt zu einer Reduktion von Wechseleingriffen und damit verbundenen Komplikationen bei und kann so zu signifikanten Kosteneinsparungen führen
MARLBOROUGH, Mass., USA (16. März 2017) Das britische National Institute for Health and Care Excellence (NICE) hat heute Leitlinien zur Anwendung medizinischer Technologie herausgegeben, die für...
- Mar 16, 2017El NICE recomienda los dispositivos TRC-D de Boston Scientific con batería ENDURALIFE™ para el tratamiento de la insuficiencia cardíaca
El Instituto Nacional británico para la Salud y la Excelencia en la Atención médica (NICE) ha emitido una recomendación sobre tecnología médica a favor del uso de los desfibriladores con...
-
Feb 6, 2017
Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...
-
Feb 6, 2017
Introduciamo la tecnologia SmartCRT™ che fornisce stimolazione multisito con una batteria la cui durata arriva a 13,3 anni1 Boston Scientific Europa ha annunciato oggi l’immissione sul mercato...
Dec 1, 2016Boston Scientific presenta el ureteroscopio digital flexible desechable LithoVue™ en EE.UU. y EuropaEl sistema desechable para la eliminación de cálculos permite obviar el mantenimiento, el reprocesado y la esterilizaciónBoston Scientific Corporation (NYSE: BSX) ha anunciado hoy la presentación en EE.UU. y Europa de LithoVue™, un ureteroscopio digital, flexible y desechable, destinado a intervenciones...
-
Oct 14, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Oct 14, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Oct 13, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Oct 13, 2016
Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day. A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the...
-
Sep 20, 2016
Boston Scientific Corporation (NYSE: BSX) ha ottenuto il marchio CE per il sistema valvolare LOTUS Edge™, un dispositivo di nuova generazione per l’impianto transcatetere della valvola aortica...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) ha recibido el marcado CE para el sistema valvular LOTUS Edge™, una válvula aórtica percutánea (TAVI) de nueva generación de la empresa. LOTUS Edge...
-
Aug 5, 2016
Boston Scientific Corporation (NYSE: BSX) ha concluso l’accordo annunciato in precedenza con Endo International plc (NASDAQ: ENDP) (TSX: ENL) per l’acquisto dei settori Salute Maschile e...
-
Jun 14, 2016Studies show that treatment is less costly and has lower hospital re-admissions
Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...
-
May 19, 2016
Abschließende Fünf-Jahres-Ergebnisse der EVOLVE-Studie zeigen Langzeit-Sicherheit und -Wirksamkeit des SYNERGY-Stents von Boston Scientific (NYSE: BSX) zur Behandlung von Patienten mit neu...
-
May 19, 2016Final, 5-year results from the EVOLVE Trial evaluating the Boston Scientific (NYSE: BSX) SYNERGY Stent support long-term safety and efficacy for the treatment of patients with de novo coronary artery disease.
The final 5 year results of the EVOLVE Trial reinforce earlier findings of sustained performance of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System, with no stent thrombosis (ST), a...
-
May 19, 2016
Die Resultate der Post-Marketing-Studie mit mehr als 1.000 Patienten belegen Sicherheit und Wirksamkeit einer Transkatheter-Aortenklappen-Implantation (TAVI) mittels der LOTUS™-Klappe im...
-
May 18, 2016Risultati a tre mesi su più di 1000 pazienti in tutta Europa, incentrati principalmente sul regime farmacologico post-procedurale, sull'impatto dell’esperienza del centro e sull’incidenza di leak peri-device.
I risultati a tre mesi del registro EWOLUTION (REgistry on WATCHMAN Outcomes in Real-Life Utilization) hanno dimostrato che la chiusura dell’auricola sinistra con il dispositivo WATCHMAN™ di...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Outcomes from this post market study of more than 1,000 patients demonstrate the safety and efficacy of transcatheter aortic valve implantation (TAVI) with the LOTUS™ Valve in routine clinical practice.
Results from the RESPOND Study evaluating the Boston Scientific (NYSE: BSX) LOTUS™ Valve demonstrated excellent outcomes of key safety and efficacy endpoints through 30 days post implant...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 16, 2016
Drei-Monats-Ergebnisse von mehr als 1.000 Patienten in ganz Europa konzentrieren sich auf das postprozedurale Medikationsregime, die Erfahrungen in den Zentren sowie auf potenzielle Lecks der...
-
May 13, 2016WATCHMAN™ LAAC Device EWOLUTION Real-World Outcomes to be Featured as Late Breaking Clinical Trial
Boston Scientific (NYSE: BSX) today announced its schedule of key data, that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...